Abstract Library

#4053 Risk factors of clinically relevant pancreatic fistula after pancreaticoduodenectomy for pancreatic neuroendocrine tumors – Single-center retrospective study

Introduction: Clinically relevant pancreatic fistula (CR-POPF) significantly worsens the postoperative course after pancreaticoduodenectomy (PD).

Conference:

Presenting Author:

Authors: Gajda M, Grudzińska E, Mrowiec S,

Keywords: pancreatic neuroendocrine tumor (PNET), pancreaticoduodenectomy (PD), clinically relevant pancreatic fistula (CR-POPF),

#4009 Hepatic metastatic model establishment of pancreatic neuroendocrine tumor by hemi-splenectomy

Introduction: The early diagnosis of pancreatic neuroendocrine tumor (pNET) patients is hard, and 60% patients are diagnosed with liver metastasis at the first visit to hospital. These patients are not suitable for surgery, which is the preferred and most effective option for pNETs. And liver metastasis promises worse outcome for patients.

Conference:

Presenting Author: Wang F

Authors: Wang F, Jing D, Zhou C, Qin Y, Chen J,

Keywords: Pancreatic neuroendocrine tumor, liver metastases, murine model, hemi-splenectomy, hepatic metastatic model,

#4008 Mapping of lymph node metastasis in non-functional pancreatic neuroendocrine tumors: A retrospective analysis of 455 patients

Introduction: Radical surgery is the best and effective option for resectable pancreatic neuroendocrine tumor (pNET) patients. However, lymphadenectomy in pNET surgery remains controversial, especially for small tumors.

Conference:

Presenting Author: Wang F

Authors: Wang F, Jing D, Zhou C, Qin Y, Chen J,

Keywords: Pancreatic neuroendocrine tumor, Lymph node metastasis, Lymph node dissection, Metastasis rate, Lymph node,

#3893 Pancreatic neuroendocrine tumor associated hypophosphatemia due to tumor-induced osteomalacia – A case report

Introduction: Tumor-induced osteomalacia (TIO) is a rare syndrome characterised by hypophosphataemia and osteomalacia with renal phosphate wasting caused by elevated levels of fibroblast growth factor 23 (FGF23) in the setting of tumor. The primary tumor is typically found in bone or soft tissue.

Conference:

Presenting Author:

Authors: Storan D, Almeamar H, O'Shea D, O'Toole D, Crowley R,

Keywords: pNET, pancreas, hypophosphataemia, osteomalacia, fgf23,

#3885 Adaptive immunosuppressive resistance mechanisms towards antiangiogenic immunotherapies revealed in a pancreatic neuroendocrine tumor (PNET) model

Introduction: Pancreatic neuroendocrine tumors (PNETs) are mostly indolent but can achieve malignancy. Surgery is the only approved first-line therapy. Kinase inhibitors and radiotherapy for unresectable PNETs are non-curative and targeted therapies are currently lacking for PNETs. However, immune checkpoint inhibitors have created a paradigm shift in cancer therapy with significant increase in overall survival, but are curative only in a subset of patients, partly due to limited T cell infiltration, especially in angiogenic and cold tumors like PNETs. Parallelly, antiangiogenic therapy increases lymphocyte infiltration by normalising the tumor vasculature. Tallying antiangiogenic to immunotherapies (AI) has provided improved survival benefits for patients of advanced RCCs and HCCs, while other cancers like glioblastoma remain highly resistant.

Conference:

Presenting Author:

Authors: John Robbert D, Guyot M, Killian T, Verslype C, Lambrechts D,

Keywords: Pancreatic neuroendocrine tumor, Antiangiogenic immunotherapy, single cell transcriptomics, Immunosuppression,